Loading...
Future agents and treatment directions in multiple myeloma
The development of bortezomib and IMIDs resulted in a revolution in the treatment of MM. Moreover, second-generation proteasome inhibitors (carfilzomib) and IMIDs (pomalidomide) have recently been approved. Nevertheless, the incurability of this disease requires other drugs with different mechanisms...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2013
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4157182/ https://ncbi.nlm.nih.gov/pubmed/24350987 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/17474086.2014.858595 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|